SAN DIEGO, Apr 07, 2009 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for first quarter 2009 following the close of market on Tuesday, April 21, 2009.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay Flatley, President and Chief Executive Officer, and Christian Henry, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on Tuesday, April 21, 2009. Interested parties may listen to the call by dialing 1-800-901-5218 (passcode: 98415934), or if outside North America, by dialing +1-617-786-4511 (passcode: 98415934). Individuals may access the live teleconference under the "Corporate/Investor Information" tab of Illumina's web site at www.illumina.com.
A replay of the conference call will be available from 5:00pm Pacific Time (8:00pm Eastern Time) on April 21, 2009 through April 28, 2009 by dialing 1-888-286-8010 (passcode: 36595744) or if outside North America, by dialing +1-617-801-6888 (passcode: 36595744).
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, DNA analysis, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray(TM), VeraCode(R), and Solexa(R) technologies and to deploy new sequencing, gene expression, and DNA analysis products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator(R) oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
SOURCE: Illumina, Inc.
Media:
Maurissa Bornstein
Public Relations Manager
858-332-4055
mbornstein@illumina.com
or
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com